HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study
Observational Study
[키워드] 95% CI
adjusted
age
Analysis
analyzed
Anticoagulant
association
calculated
cardiovascular disease
cause
Coagulation
Cohort
cohort study
Comorbidity
condition
COVID-19
COVID-19 mortality
COVID-19 pandemic
defined
determine
diagnosed
died
drug
drug regimens
example
Factors
female
Follow-up
groups
hazard
hazard ratio
Health
health condition
healthcare
heterogeneity
HMG-CoA reductase
HRs
hyperlipidemia
immune
immune system
include
individual
inhibitor
initiated
ischemic heart disease
less
limitation
lower risk
male
mechanisms
Mortality
multivariable
multivariable Cox regression
observational study
Older
performed
pleiotropic effect
population-based cohort
prescription
previous study
randomized clinical trials
randomized trial
recommendation
recommendations
recorded
registry
researcher
resulting
risk
sensitivity analysis
statin
Study design
Support
survival
Swedish
therapeutic effect
Topic
Treatment
Trial
while
with COVID-19
[DOI] 10.1371/journal.pmed.1003820 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1371/journal.pmed.1003820 PMC 바로가기 [Article Type] Observational Study